"CD5 Antigens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
| Descriptor ID |
D018956
|
| MeSH Number(s) |
D23.050.301.264.051.101 D23.050.301.264.894.101 D23.101.100.150.101 D23.101.100.894.101
|
| Concept/Terms |
CD5 Antigens- CD5 Antigens
- T1 Antigen
- Leu-1 Antigen
- Leu 1 Antigen
- CD5 Antigen
- Antigen, CD5
- Antigens, CD5
|
Below are MeSH descriptors whose meaning is more general than "CD5 Antigens".
- Chemicals and Drugs [D]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, B-Lymphocyte [D23.050.301.264.051]
- CD5 Antigens [D23.050.301.264.051.101]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CD5 Antigens [D23.050.301.264.894.101]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, B-Lymphocyte [D23.101.100.150]
- CD5 Antigens [D23.101.100.150.101]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CD5 Antigens [D23.101.100.894.101]
Below are MeSH descriptors whose meaning is more specific than "CD5 Antigens".
This graph shows the total number of publications written about "CD5 Antigens" by people in this website by year, and whether "CD5 Antigens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 2 | 0 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 2 | 3 |
| 2009 | 1 | 2 | 3 |
| 2010 | 1 | 1 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 1 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 2 | 5 |
| 2022 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "CD5 Antigens" by people in Profiles.
-
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity. Cell Rep Med. 2024 Jul 16; 5(7):101628.
-
Clinicopathologic Features and Genomic Signature of De Novo CD5 + Diffuse Large B-Cell Lymphoma : A Multicenter Collaborative Study. Am J Surg Pathol. 2022 11 01; 46(11):1533-1544.
-
High self-reactivity drives T-bet and potentiates Treg function in tissue-specific autoimmunity. JCI Insight. 2018 01 25; 3(2).
-
Somatic CLL mutations occur at multiple distinct hematopoietic maturation stages: documentation and cautionary note regarding cell fraction purity. Leukemia. 2018 04; 32(4):1041-1044.
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
-
Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017 Apr; 98(4):415-421.
-
Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 05; 15(5):610-618.
-
Primary adrenal diffuse large B-cell lymphoma positive for CD5 and CD10. Rinsho Ketsueki. 2017; 58(2):161-164.
-
CD5 expression is regulated during human T-cell activation by alternative polyadenylation, PTBP1, and miR-204. Eur J Immunol. 2016 06; 46(6):1490-503.
-
CD123 Immunohistochemical Expression Is a Specific But Insensitive Marker of Early T-precursor Leukemia. Appl Immunohistochem Mol Morphol. 2016 Jan; 24(1):e4-5.